Archives

by in
Entry Author Date Location
ARCH Venture Exploits IPO Window To Raise $400M Fund, Its Eighth 08/27/14 Seattle
Coelacanths And Other IPO Thoughts Before The Autumn Markets Return 08/26/14 National
Roche To Pay $8.3B For Intermune: Who’s Next In Pulmonary Fibrosis? 08/25/14 San Francisco
East Coast Biotech Roundup: NJ Blues, Genzyme, Amicus, Biogen & More 08/25/14 Boston
Join Us For “Boston’s Life Science Disruptors” on Oct. 8 08/21/14 Boston
NJ’s Medicine Chest Thins Again as GE Health Unit Heads for MA 08/19/14 Boston
Cellectar Biosciences Makes Nasdaq Debut With $12.5M Stock Offering 08/15/14 Wisconsin
East Coast Biotech Roundup: Amicus, Accelerator, Seventh Sense, & More 08/15/14 Boston
For Exact Sciences, It’s Put Up or Shut Up Time For Colon Cancer Test 08/14/14 Wisconsin
Novartis Helps Pour $16M Into Seventh Sense for Pain-Free Blood Tests 08/13/14 Boston
Tokai, Chasing the Field in Prostate Cancer, Files For IPO 08/12/14 Boston
While Protesters Rage Against Tech Giants, Biotech Drives Quietly By 08/12/14 National
Standing on a Ledge Once Again, Amicus Holds Breath for Latest Study 08/11/14 New York
T2 Biosystems Sputters Through IPO Queue, Raises $57M 08/07/14 Boston
With $310M and Public Investors Aboard, Is a Juno IPO Next? 08/05/14 Seattle
Enumeral Raises $21.5M, Heads to the OTC Via Reverse Merger 08/04/14 Boston
East Coast Biotech Roundup: Emulate, Accelerator, Retrophin, & More 08/01/14 Boston
With $2M Seed, Perlstein Lab Tests Unorthodox Rare-Disease Plan 07/31/14 San Francisco
To Solve Alzheimer’s Mystery, Better Biological Clues Sorely Needed 07/29/14 National
Emulate Scores $12M to Shake Up Drug Testing With Organs on Chips 07/28/14 Boston
Sarepta Abruptly Fires CSO and RNA Vet Krieg 07/24/14 Boston
BioCryst Bets on New Ebola Drug to Fight Bioterror, Outbreak Threats 07/24/14 Raleigh Durham
Xconomy Launches in Raleigh-Durham—10th Cluster in Our Network 07/24/14 National
J&J Immunology Exec on Investing at the Crossroads of the Microbiome 07/24/14 National
Synlogic Gets $30M From Atlas, NEA to Turn Smart Bugs Into Drugs 07/22/14 Boston
Cellectar, an OTC Stock, Eyes Nasdaq Jump to Boost Profile, Prospects 07/22/14 Wisconsin
East Coast Biotech Roundup: Acceleron, Seres, Sage, & More 07/18/14 Boston
Sage, Despite Industry-Wide Pullback, Scores $90M in Upsized IPO 07/17/14 Boston
How a Little Serendipity Led Acceleron to a Crippling Blood Disease 07/17/14 Boston
Seres Makes Push for First Drug, and IPO, of Microbiome Era 07/16/14 Boston
Page 2 of 86 « previous page · next page »